<DOC>
	<DOC>NCT00520403</DOC>
	<brief_summary>This single arm study will assess the efficacy and safety of Avastin in combination with interferon alfa-2a and vinblastine as first line treatment in patients with metastatic renal cell cancer. Patients will receive Avastin (15mg/kg iv) every 3 weeks, interferon alfa-2a 3 times weekly (3 Mio IU sc escalating to 18 Mio sc) and vinblastine (0.1mg/kg iv) every 3 weeks. The anticipated time on study treatment is until tumor progression, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; metastatic renal cell cancer of predominantly clear cell type; &gt;=1 measurable lesion. prior treatment with chemotherapy, cytokine or tyrosine kinase inhibitor therapy for metastatic renal cell cancer; ongoing or recent need for full therapeutic dose of anticoagulants or chronic daily treatment with aspirin (&gt;325mg/day); clinically significant cardiovascular disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>